Ulinastatin treatment mitigates glycocalyx degradation and associated with lower postoperative delirium risk in patients undergoing cardiac surgery: a multicentre observational study
UTI administration may mitigate glycocalyx degradation, potentially lowering the risk of POD in cardiac surgery patients, offering valuable insights for future interventions to prevent POD and enhance patient outcomes. Trial registration number ClinicalTrials.gov (No. NCT06268249). Retrospectively registered 4 February 2024.
Authors
- Qin Zhang (ORCID: https://orcid.org/0000-0002-5664-5823)
- Tingting Xu (ORCID: https://orcid.org/0000-0003-4643-9441)
- Juan Tan
- Fang Luo (ORCID: https://orcid.org/0000-0002-3584-0355)
- Rongxue Wu (ORCID: https://orcid.org/0000-0003-4857-4655)
- Shaobing Yang (ORCID: https://orcid.org/0000-0002-6566-5316)
- Hang Ruan (ORCID: https://orcid.org/0000-0001-7738-0177)
- Xiao Ran (ORCID: https://orcid.org/0000-0001-5025-2538)
- Jieqiong Liu
Institutions
- University of Chicago (US)
- Tongji Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Critical Care
- Published
- 2025-01-29
- DOI
- https://doi.org/10.1186/s13054-025-05296-9
- Citations
- 2
- Primary Topic
- Intensive Care Unit Cognitive Disorders
- Type
- article
- Field-Weighted Citation Impact
- 3.09
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Hubei Province